The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Denosumab Is Effective for Glucocorticoid-Induced Osteoporosis

Denosumab Is Effective for Glucocorticoid-Induced Osteoporosis

May 15, 2018 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis. Glucocorticoid exposure is closely associated with osteoporosis, and 35% of patients who receive chronic treatment with glucocorticoids go on to have vertebral fractures. These patients require both primary and secondary fracture prevention. Although the bisphosphonate risedronate is frequently prescribed to treat glucocorticoid-induced osteoporosis, many patients never receive preventive treatment. Several randomized clinical trials have evaluated different therapies for glucocorticoid-induced osteoporosis. These treatments include alendronate, risedronate, zoledronic acid and teriparatide, all of which appear to be effective at maintaining or increasing bone mass.

You Might Also Like
  • FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Glucocorticoid-Induced Osteoporosis
Also By This Author
  • Anti-TNF-Alpha Agents May Improve Endothelial Function Patients with RA

A recent study identified the RANKL inhibitor denosumab as another useful treatment option for patients newly initiating or continuing glucocorticoid therapy who are at increased risk for fractures. Kenneth G. Saag, MD, professor at the University of Alabama, Birmingham, published the 12-month results of the 24-month randomized, active-controlled trial online April 6 in Lancet Diabetes Endocrinology.1 The study is one of the largest, randomized, controlled trials on glucocorticoid-induced osteoporosis and the first large, randomized, controlled trial of denosumab in patients with glucocorticoid-induced osteoporosis who were either prevalent glucocorticoid users or newly initiating glucocorticoid therapy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We chose risedronate as the active comparator for three reasons,” explain the authors in their discussion. “First, our study was modeled on a study of zoledronic acid for treatment and prevention of glucocorticoid-induced osteoporosis, in which risedronate was the active comparator. Second, the non-inferiority margin for an active-controlled study is best derived from the treatment effect of the chosen active control in a placebo-controlled study in the same population of interest, and such data were available for risedronate. Finally, risedronate was approved and available in all countries participating in this global study.”

Of the 795 patients in the study, 505 were continuing glucocorticoid treatment and 290 were initiating glucocorticoid treatment. The patients were enrolled in 79 centers worldwide and randomly assigned to receive treatment with either denosumab or risedronate. The investigators found that denosumab was both non-inferior and superior to risedronate in patients already taking or newly initiating glucocorticoid therapy. Specifically, denosumab was more effective than risedronate for the improvement of bone mineral density at the lumbar spine in this patient population. Moreover, denosumab and risedronate had clinical effects similar to those documented in previous osteoporosis studies. Although the study included 795 patients, it was not powered to detect fracture differences between the treatment groups.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients in the two treatment groups had similar safety profiles, suggesting denosumab is well tolerated. The most common adverse events in both treatment groups were back pain and arthralgia. Previous studies found patients treated with denosumab were more likely to experience serious skin infections and a higher rate of urinary tract infections than placebo-treated patients. However, the current study found the incidence of serious adverse events, including serious infections and fractures, was similar between the groups at about 4%.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: bisphosphonates, denosumab, Glucocorticoid-Induced Osteoporosis, Osteoporosis, osteoporosis treatments, risedronate

You Might Also Like:
  • FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis
  • Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis
  • Glucocorticoid-Induced Osteoporosis
  • Supplemental Application for Denosumab Goes to FDA

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)